Bile acid-retention by native and modified oat and barley β-glucan.

Carbohydr Polym

Institute of Food, Nutrition and Health, ETH Zurich, 8092, Zurich, Switzerland. Electronic address:

Published: May 2020

Foods rich in cereal β-glucan are efficient dietary tools to help reduce serum cholesterol levels and hence the risk of cardiovascular diseases. However, β-glucan undergoes various reactions during food processing, which alter its viscous properties and interactions with components of the gastrointestinal tract. It has been proposed in the literature that oxidation and partial hydrolysis increase β-glucan's bile acid-binding activity, and therefore its effectiveness in lowering cholesterol. Here, the passage kinetics of a bile salt mix across a dialysis membrane was studied with or without oat and barley β-glucan extracts, native or modified (partial hydrolysis and oxidations by sodium periodate or TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl)). Bile acid-retention turned out to be purely a function of viscosity, with the most viscous native extracts exhibiting the strongest retardation of bile acid permeation. Opposite of what was suggested in the literature, oxidation and molecular weight reduction do not seem to increase the bile acid-binding capability of β-glucan.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carbpol.2020.116034DOI Listing

Publication Analysis

Top Keywords

bile acid-retention
8
native modified
8
oat barley
8
barley β-glucan
8
literature oxidation
8
partial hydrolysis
8
bile acid-binding
8
bile
6
β-glucan
5
acid-retention native
4

Similar Publications

knockout (KO) mice lack the liver enzyme responsible for synthesis of 6-hydroxylated muricholate bile acid species and possess a more hydrophobic human-like bile acid composition. KO mice develop cholestatic liver injury that can be prevented by the administration of an ileal bile acid transporter (IBAT) inhibitor. In this study, we investigated the potential of an ileal bile acid transporter (IBAT) inhibitor (SC-435) and steroidal farnesoid X receptor (FXR) agonist (cilofexor) to modulate established hepatobiliary injury and the consequent relationship of intrahepatic bile acid content and hydrophobicity to the cholestatic liver injury phenotype.

View Article and Find Full Text PDF

New Treatment Paradigms in Primary Biliary Cholangitis.

Clin Gastroenterol Hepatol

July 2023

Toronto Centre for Liver Disease, Division of Gastroenterology and Hepatology, University of Toronto, Toronto, Canada.

Article Synopsis
  • Primary biliary cholangitis (PBC) is a chronic autoimmune disease marked by symptoms like fatigue, itchiness, and abdominal pain, primarily affecting women and causing significant quality-of-life issues.
  • Treatment focuses on relieving cholestasis and includes first-line medications like ursodeoxycholic acid, while newer options aim to reduce fibrosis and inflammation through PPAR agonists and other agents.
  • Current research is exploring innovative therapies to manage symptoms and target underlying immune regulation, creating an optimistic outlook for individualized PBC treatment strategies.
View Article and Find Full Text PDF

Labetalol is used for the therapy of hypertension in preeclampsia. Preeclampsia is characterized by high soluble endoglin (sEng) concentration in plasma and coincides with intrahepatic cholestasis during pregnancy (ICP), which threatens the fetus with the toxicity of cumulating bile acids (BA). Therefore, we hypothesized that both labetalol and increased sEng levels worsen BA cumulation in estrogen-induced cholestasis.

View Article and Find Full Text PDF

Agroindustrial activities generate various residues or byproducts which are inefficiently utilized, impacting the environment and increasing production costs. These byproducts contain significant amounts of bioactive compounds, including dietary fiber with associated phenolic compounds, known as antioxidant dietary fiber (ADF). Phenolic compounds are related to the prevention of diseases related to oxidative stress, such as neurodegenerative and cardiovascular diseases.

View Article and Find Full Text PDF

Plumbagin ameliorates bile duct ligation-induced cholestatic liver injury in rats.

Biomed Pharmacother

July 2022

Department of Veterinary Medicine, National Chung Hsing University, Taichung City 402, Taiwan. Electronic address:

Plumbagin, a natural bicyclic naphthoquinone, has diverse pharmacological properties and biological benefits against a number of disorders, including liver disease. Though plumbagin's hepatoprotective potential attracts attention, currently no experimental evidence exists on its effectiveness against cholestatic liver injury. The present study investigated its hepatoprotection in the rat model of extrahepatic cholestasis using Bile Duct Ligation (BDL).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!